GRAL(GRAL)
GRAL
ANALYST COVERAGE6 analysts
BUY
▲ +10.2%upside to target
L $56.00
Med $65.00consensus
H $130.00PRICE
Prev Close
60.71
Open
59.81
Day Range58.26 – 60.12
58.26
60.12
52W Range29.95 – 118.84
29.95
118.84
33% of range
VOLUME & SIZE
Avg Volume
1.2M
FUNDAMENTALS
P/E Ratio
-5.7x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
TECHNICAL
RSI (14)
57
Bullish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 20
DEx-Dividend
In 90 days
Aug 17
PDividend Pay
In 97 days
Aug 24
Key MetricsTTM
Market Cap$2.53B
Revenue TTM$156.12M
Net Income TTM-$395.32M
Free Cash Flow-$291.43M
Gross Margin-14.8%
Operating Margin-348.7%
Net Margin-253.2%
Return on Equity-16.4%
Return on Assets-14.1%
Debt / Equity0.02
Current Ratio11.74
EPS TTM$-9.73
GRAL News
About
No description available.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Hans Bishop
Country
United States
Website
Abram BarthGeneral Counsel & Corporate Secretary
Joshua J. OfmanPresident & Director
Satnam AlagSenior Vice President of Software Engineering & Chief Security Officer
Aaron FreidinChief Financial Officer
Andrew John PartridgeChief Commercial Officer
Paul CiccolellaSenior Vice President of Global Development & Operations
Robert RagusaChief Executive Officer & Director
Alison HighlanderSenior Vice President of Human Resources & Head of People Team
Linda J. PetersSenior Vice President of Quality & Regulatory
Sir Harpal S. KumarChief Scientific Officer & President International
Alexis TostiVice President of Strategy & Corporate Development
Eric T. FungSenior Vice President of Clinical Development